<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Cns Pharmaceuticals, Inc. — News on 6ix</title>
<link>https://6ix.com/company/cns-pharmaceuticals-inc</link>
<description>Latest news and press releases for Cns Pharmaceuticals, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 11 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/cns-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683557d078dffbe2df0ea57f.webp</url>
<title>Cns Pharmaceuticals, Inc.</title>
<link>https://6ix.com/company/cns-pharmaceuticals-inc</link>
</image>
<item>
<title>CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline</title>
<link>https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-launches-new-corporate-strategy-focused-on-building-a-high-value-neurology-and-oncology-pipeline-14</link>
<guid isPermaLink="true">https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-launches-new-corporate-strategy-focused-on-building-a-high-value-neurology-and-oncology-pipeline-14</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>Newly formed executive team initiates global search for differentiated therapeutic assets for neurology and oncology indications, two of biopharma's largest</description>
</item>
<item>
<title>CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team</title>
<link>https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-appoints-lynne-kelley-md-facs-as-chief-medical-officer-completing-executive-leadership-team</link>
<guid isPermaLink="true">https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-appoints-lynne-kelley-md-facs-as-chief-medical-officer-completing-executive-leadership-team</guid>
<pubDate>Mon, 02 Mar 2026 13:25:00 GMT</pubDate>
<description>Dr. Kelley adds two decades of highly relevant drug development and regulatory strategy experience spanning oncology, rare diseases and CNS Newly formed executive team is committed to execution and company evolution focused on patient and stakeholder ...</description>
</item>
<item>
<title>CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation</title>
<link>https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-appoints-multiple-key-132500001</link>
<guid isPermaLink="true">https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-appoints-multiple-key-132500001</guid>
<pubDate>Tue, 17 Feb 2026 13:25:00 GMT</pubDate>
<description>New Members of the Strengthened Leadership Team Add Decades of Operational Execution, Pipeline Optimization and Transactional Expertise to Support Company Growth and Value Creation HOUSTON, TX / ACCESS Newswire / February 17, 2026 / CNS Pharmaceuticals, ...</description>
</item>
<item>
<title>CNS Pharmaceuticals Issues Letter to Shareholders</title>
<link>https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-issues-letter-shareholders-140000389</link>
<guid isPermaLink="true">https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-issues-letter-shareholders-140000389</guid>
<pubDate>Tue, 27 Jan 2026 14:00:00 GMT</pubDate>
<description>Newly Appointed President & Chief Executive Officer, Rami Levin, Discusses Plans for a New Era at CNS Pharmaceuticals Strategic Focus, Pipeline Optimization and Formalizing Roadmap for Near and Long-Term Value Creation HOUSTON, TX / ACCESS Newswire ...</description>
</item>
<item>
<title>CNS Pharmaceuticals Issues Letter to Shareholders </title>
<link>https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-issues-letter-to-shareholders</link>
<guid isPermaLink="true">https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-issues-letter-to-shareholders</guid>
<pubDate>Tue, 27 Jan 2026 05:00:00 GMT</pubDate>
<description>Newly Appointed President & Chief Executive Officer, Rami Levin, Discusses Plans for a New Era at CNS PharmaceuticalsStrategic Focus, Pipeline Optimization</description>
</item>
<item>
<title>CNS Pharmaceuticals Announces CEO Transition</title>
<link>https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-announces-ceo-transition-120000083</link>
<guid isPermaLink="true">https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-announces-ceo-transition-120000083</guid>
<pubDate>Wed, 17 Dec 2025 12:00:00 GMT</pubDate>
<description>Industry veteran Rami Levin, MBA appointed as President & Chief Executive Officer HOUSTON, TX / ACCESS Newswire / December 17, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a biopharmaceutical company specializing in the ...</description>
</item>
<item>
<title>CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-reports-third-quarter-133500002</link>
<guid isPermaLink="true">https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-reports-third-quarter-133500002</guid>
<pubDate>Mon, 17 Nov 2025 13:35:00 GMT</pubDate>
<description>Cash expected to fund operations into the second half of 2026 Company focused on advancing next-generation anti-cancer therapies derived from well-established drug classes, now engineered to cross the blood-brain barrier, potentially enhancing efficacy ...</description>
</item>
<item>
<title>CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting</title>
<link>https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-announces-acceptance-three-134500171</link>
<guid isPermaLink="true">https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-announces-acceptance-three-134500171</guid>
<pubDate>Mon, 10 Nov 2025 13:45:00 GMT</pubDate>
<description>HOUSTON, TX / ACCESS Newswire / November 10, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and ...</description>
</item>
<item>
<title>CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-present-h-c-131500681</link>
<guid isPermaLink="true">https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-present-h-c-131500681</guid>
<pubDate>Wed, 03 Sep 2025 13:15:00 GMT</pubDate>
<description>HOUSTON, TX / ACCESS Newswire / September 3, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and ...</description>
</item>
<item>
<title>CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-reports-second-quarter-120500294</link>
<guid isPermaLink="true">https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-reports-second-quarter-120500294</guid>
<pubDate>Fri, 15 Aug 2025 12:05:00 GMT</pubDate>
<description>Strong cash position of $12.1 million expected to fund operations into the second half of 2026 Driving lead program, TPI 287, towards Phase 2 study for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire / August 15, 2025 / CNS ...</description>
</item>
<item>
<title>CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech</title>
<link>https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-present-webull-financial-131500815</link>
<guid isPermaLink="true">https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-present-webull-financial-131500815</guid>
<pubDate>Thu, 14 Aug 2025 13:15:00 GMT</pubDate>
<description>- Live video webcast on Tuesday, August 19th at 2:40 PM ET HOUSTON, TX / ACCESS Newswire / August 14, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments ...</description>
</item>
<item>
<title>CNS Pharmaceuticals to Participate in the Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference</title>
<link>https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-participate-virtual-investor-124500024</link>
<guid isPermaLink="true">https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-participate-virtual-investor-124500024</guid>
<pubDate>Tue, 22 Jul 2025 12:45:00 GMT</pubDate>
<description>– Video webcast now available on-demand HOUSTON, TX / ACCESS Newswire / July 22, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for ...</description>
</item>
<item>
<title>CNS Pharmaceuticals Announces Reverse Stock Split</title>
<link>https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-announces-reverse-stock-120000322</link>
<guid isPermaLink="true">https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-announces-reverse-stock-120000322</guid>
<pubDate>Fri, 18 Jul 2025 12:00:00 GMT</pubDate>
<description>HOUSTON, TX / ACCESS Newswire / July 18, 2025 /CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central ...</description>
</item>
<item>
<title>CNS Pharmaceuticals Announces Reverse Stock Split </title>
<link>https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-announces-reverse-stock-split</link>
<guid isPermaLink="true">https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-announces-reverse-stock-split</guid>
<pubDate>Fri, 18 Jul 2025 04:00:00 GMT</pubDate>
<description>HOUSTON, TX / ACCESS Newswire / July 18, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in</description>
</item>
<item>
<title>CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment</title>
<link>https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-participates-virtual-investor-133200426</link>
<guid isPermaLink="true">https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-participates-virtual-investor-133200426</guid>
<pubDate>Wed, 09 Jul 2025 13:32:00 GMT</pubDate>
<description>HOUSTON, TX / ACCESS Newswire / July 9, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central ...</description>
</item>
<item>
<title>CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287</title>
<link>https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-announces-virtual-investor-131500732</link>
<guid isPermaLink="true">https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-announces-virtual-investor-131500732</guid>
<pubDate>Tue, 24 Jun 2025 13:15:00 GMT</pubDate>
<description>Moderated discussion with founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital, Dr. Erin Dunbar HOUSTON, TX / ACCESS Newswire / June 24, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the ...</description>
</item>
<item>
<title>CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit</title>
<link>https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-chief-medical-officer-120500114</link>
<guid isPermaLink="true">https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-chief-medical-officer-120500114</guid>
<pubDate>Thu, 05 Jun 2025 12:05:00 GMT</pubDate>
<description>In person presentation today, Thursday, June 5th at 9:30 AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire / June 5, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ...</description>
</item>
<item>
<title>CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-reports-first-quarter-120500273</link>
<guid isPermaLink="true">https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-reports-first-quarter-120500273</guid>
<pubDate>Fri, 16 May 2025 12:05:00 GMT</pubDate>
<description>Cash expected to fund operations into the second half of 2026 Advancing development strategy for lead program TPI 287 to commence Phase 2 study around year end 2025 for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire / May ...</description>
</item>
<item>
<title>CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules</title>
<link>https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-announces-pricing-5-133500354</link>
<guid isPermaLink="true">https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-announces-pricing-5-133500354</guid>
<pubDate>Tue, 13 May 2025 13:35:00 GMT</pubDate>
<description>HOUSTON, TX / ACCESS Newswire / May 13, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central ...</description>
</item>
<item>
<title>CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287</title>
<link>https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-acquires-orphan-drug-110000963</link>
<guid isPermaLink="true">https://6ix.com/company/cns-pharmaceuticals-inc/news/cns-pharmaceuticals-acquires-orphan-drug-110000963</guid>
<pubDate>Tue, 13 May 2025 11:00:00 GMT</pubDate>
<description>Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that appears to cross the blood-brain barrier and has published clinical efficacy data in glioblastoma multiforme (GBM) Management releases "What This Means" segment discussing ...</description>
</item>
</channel>
</rss>